title: Association between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk Factors: Role of Total and Undercarboxylated Osteocalcin in Patients with Type 2 Diabetes.
abstract: Studies have demonstrated that total osteocalcin (TOC) is associated with metabolic syndrome (MetS) and therefore might influence the risk of cardiovascular disease in humans. Undercarboxylated osteocalcin (uOC) regulates insulin secretion and sensitivity in mice, but its relation to MetS in humans is unclear. We aimed to determine whether uOC is related to MetS and/or its individual components and other cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM), and whether TOC and uOC have utility in predicting the cardiovascular risk. We studied 203 T2DM patients with and without MetS. MetS was defined based on the NCEP-ATP III criteria. A correlation analysis was performed between the three outcome variables: (i) TOC, (ii) uOC, and (iii) carboxylated osteocalcin (cOC) and MetS components and other cardiovascular risk factors. Both TOC and uOC were significantly lower in patients with MetS compared to those without MetS, independent of body mass index. In patients with MetS, uOC was significantly and positively correlated with HDL cholesterol, while TOC was significantly and negatively correlated with serum triglycerides. We report for the first time that uOC is related to lipid indices in patients with T2DM. Further studies are necessary to determine whether uOC can be utilized for cardiovascular risk assessments in these patients.
authors: Obesity Research Center, College of Medicine, King Saud University, P.O. Box 2925 (98), Riyadh 11461, Saudi Arabia ; Department of Medicine, College of Medicine, King Saud University, P.O. Box 2925 (38), Riyadh 11461, Saudi Arabia.
authors: Assim A
authors: AA
authors: Alfadda
authors: Afshan
authors: A
authors: Masood
authors: Shaffi Ahamed
authors: SA
authors: Shaik
authors: Hafedh
authors: H
authors: Dekhil
authors: Michael
authors: M
authors: Goran
references: J Intern Med. 2004 Feb;255(2):188-205
references: 14746556
references: Biochem Biophys Res Commun. 1997 Feb 13;231(2):442-6
references: 9070297
references: J Clin Endocrinol Metab. 2009 Mar;94(3):827-32
references: 19088165
references: Cell. 2007 Aug 10;130(3):456-69
references: 17693256
references: Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1474-8
references: 20395593
references: Bone. 2011 Apr 1;48(4):720-5
references: 21185419
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: Endocrinology. 1994 Sep;135(3):929-37
references: 8070388
references: Clin Chim Acta. 2010 Dec 14;411(23-24):2054-7
references: 20831864
references: Osteoporos Int. 2012 Feb;23(2):599-606
references: 21359669
references: Ann Clin Biochem. 2000 Jul;37 ( Pt 4):432-46
references: 10902858
references: Am J Clin Nutr. 2009 Nov;90(5):1230-5
references: 19776145
references: Am J Cardiol. 2006 Nov 15;98(10):1369-73
references: 17134631
references: Obesity (Silver Spring). 2012 Nov;20(11):2194-201
references: 22573135
references: Metabolism. 2011 Aug;60(8):1186-92
references: 21353261
references: Diabetes Care. 2003 Jul;26(7):2207-8
references: 12832337
references: Obes Surg. 2008 Sep;18(9):1134-43
references: 18563500
references: Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5266-70
references: 18362359
references: Osteoporos Int. 2011 Jan;22(1):187-94
references: 20165834
references: Lancet. 2001 Dec 15;358(9298):2026-33
references: 11755609
references: Clin Endocrinol (Oxf). 2013 Feb;78(2):242-7
references: 22435398
references: Am J Cardiol. 2001 Oct 11;88(7B):23J-27J
references: 11595195
references: Osteoporos Int. 2012 Feb;23(2):761-70
references: 21437719
references: J Bone Miner Res. 2009 May;24(5):785-91
references: 19063687